Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
31 hedge funds and large institutions have $4.07M invested in Sophiris Bio, Inc. in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
21% less capital invested
Capital invested by funds: $5.18M → $4.07M (-$1.11M)
84% less call options, than puts
Call options by funds: $40K | Put options by funds: $248K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$197K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$94.1K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$37.9K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$35.2K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMV
Sofinnova Management VIII
Menlo Park,
California
|
-$566K |
| 2 |
Millennium Management
New York
|
-$105K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$33K |
| 4 |
Squarepoint
New York
|
-$13.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.91K |
SPHS Hedge Fund Activity: Q2 2017 in Review
31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q2 2017, worth a combined $4.07M — down 21% from $5.18M a quarter earlier.
Fund positioning in SPHS was balanced in Q2 2017: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $197K. The largest seller was Sofinnova Management VIII, exiting entirely with an estimated $566K sold.
- 31 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $4.07M of Sophiris Bio, Inc. stock for Q2 2017, down 21% quarter-over-quarter.
- 5 funds opened new Sophiris Bio, Inc. positions in Q2 2017 and 5 closed out, a net change of 0 holders.
- The largest Sophiris Bio, Inc. buyer in Q2 2017 was BlackRock, an estimated $197K added.
- The largest Sophiris Bio, Inc. seller in Q2 2017 was Sofinnova Management VIII, an estimated $566K sold.
Based on aggregated 13F filings for Q2 2017.